The natural history of tardive dyskinesia

Journal of Clinical Psychopharmacology

Volumn 8, Issue 4, 1988, Pages 31S-37S

  George, Gardos ^a,b   Jonathan O , Cole ^b   David, Haskell ^c   David, Marby ^b   Susan Schniebolk, Paine ^b   Patricia, Moore ^c  

^a West Ros Park Mental Health Center ^*  (United States)

^b MCLEAN HOSPITAL   (United States)

^c Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; CLINICAL ARTICLE; DYSTONIA; HUMAN; TARDIVE DYSKINESIA;

ADULT; AGING; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMAN; MALE; MIDDLE AGE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023718620     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, reserpine and electroconvulsive therapy. Psychopharmacology 1960;1:408–18.
2. Hunter R, Earl CJ, Thornicroft S. An apparently irreversible syndrome of abnormal movements following phenothiazine medica-tion. Proc R Soc Med 1964;57:24–8.
3. Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull 1979;5:251–92.
4. Casey DE. Spontaneous and tardive dyskinesia: clinical and laboratory studies. J Clin Psychiatry 1985;46:42–7.
5. Gardos G, Cole JO. The prognosis of tardive dyskinesia. J Clin Psychiatry 1983;44:177–9.
6. Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive dyskinesia: are first signs reversible? Am J Psychiatry 1977;134:84–7.
7. Wegner J, Kane J. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry 1982;139:368–9.
8. Klawans HL, Tanner DM, Barr A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 1984;7:153–9.
9. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia—with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 1985;34:211–9.
10. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254–8.
11. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982.
12. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? In: Bannet J, Belmaker RH, eds. Modern problems in psychiatry. Basel, Switzerland: S Karger, 1983:65–79.
13. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare,1976:534–7.
14. Simpson GM, Lee JH, Zoubok B, Gardos G, Cole JO. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171–9.
15. Simpson G, Angus J. A rating scale for extrapyramidal effects. Acta Psychiatr Scand 1970;(Suppl 212):11–9.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1961;10:799–812.
17. Endicott J, Spitzer R, Fleiss J, Cohen J. The Global Assessment Scale. Arch Gen Psychiatry 1976;33:766–71.
18. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–7.
19. Crane GE. Tardive dyskinesia: a review. In: Boissier JR, Hippius H, Pichot P, eds. Neuropsychopharmacology. Elsevier, Amsterdam: Excerpta Medica, 1975:346–54.
20. Degkwitz R, Consbruch U, Haddenbrock S, Neusch B, Oehiert W, Unsold R. Therapeutische Risiken bei der Langzeitbehandlung mit Neuroleptika und Lithium: klinische, histologische and biochemische Befunde. Nervenarzt 1976;47:81.
21. Smith JM, Burke MP, Moon CO. Long-term changes in AIMS ratings and their relation to medication history. Psychopharmacol Bull 1981;17:120–1.
22. Gibson AC. Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Acta Psychiatr Scand 1981;63:111–6.
23. Barnes TRE, Kidger T, Gore SM. Tardive dyskinesia: a 3-year follow-up study. Psychol Med 1983;13:71–81.
24. Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five-year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986;22:259–63.
25. Gardos G, Perenyi A, Cole JO, Samu I, Kocsis E, Casey DE. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology 1988;1:169–172.
26. Mehta D, Mehta S, Mathew P. Tardive dyskinesia in psychogeriatric patients: a five-year follow-up study. J Am Geriatr Soc 1977;25:545–7.
27. Seeman MV. Tardive dyskinesia: two-year recovery. Compr Psychiatry 1981;22:189–92.
28. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: a two-year follow-up study. Psychosomatics 1984;25:852–5.
29. Casey DE, Povisen UJ, Meidahl B, Gerlach J. Neurolepticinduced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol Bull 1986;22: 250–3.
30. Gardos G, Cole JO. Problems in the assessment of tardive dyskinesia. In: Fann WE, Smith RC, Davis JM, et al, eds. Tardive dyskinesia: research and treatment. New York: Spectrum, 1980:201–214.
31. Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37:1368–73.
32. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry 1984;41:1030–5.